B Cell Lymphoma Clinical Trial
Official title:
Phase I/II Study to Evaluate Treatment of Relapsed or Refractory Leukemia and Lymphoma With Universal CRISPR-Cas9 Gene-Editing CAR-T Cells Targeting CD19 and CD20 or CD22
CD19-directed CAR-T cell therapy has shown promising results for the treatment of relapsed or refractory B-cell malignancies; however, a subset of patients relapse due to the loss of CD19 in tumor cells. Dual Specificity CD19 and CD20 or CD22 CAR-T cells can recognize and kill the CD19 negative malignant cells through recognition of CD20 or CD22. This is a phase 1/2 study designed to determine the safety of the allogenic gene-edited dual specificity CD19 and CD20 or CD22 CAR-T cells and the feasibility of making enough to treat patients with relapsed or refractory hematological malignancies.
1. PRIMARY OBJECTIVES:
1. To evaluate the feasibility and safety of universal dual specificity CD19 and CD20
or CD22 CAR-T cells in patients with relapsed or refractory leukemia and lymphoma.
2. To evaluate the duration of in vivo persistence of adoptively transferred T cells,
and the phenotype of persisting T cells. Real Time polymerase chain receptor
(RT-PCR) and Flow cytometry(FCM) analysis of PB,BM and lymph node will be used to
detect and quantify survival of universal dual specificity CD19 and CD20 or CD22
CAR-T cells over time.
2. SECONDARY OBJECTIVES:
1. For patients with detectable disease, measure anti-tumor response due to universal
dual specificity CD19 and CD20 or CD22 CAR-T cell infusions.
2. Determine if cellular or humoral host immunity develops against the murine
anti-CD19, and assess correlation with loss of detectable universal dual
specificity CD19 and CD20 or CD22 CAR-T cells (loss of engraftment).
The CAR-T cells will be administered by i.v. injection over 20-30 minutes as a using a "split
dose" approach to dosing: 10% on day 0, 30% on day 1 and 60% on day 2.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001512 -
Active Specific Immunotherapy for Follicular Lymphomas With Tumor-Derived Immunoglobulin Idiotype Antigen Vaccines
|
Phase 1 | |
| Recruiting |
NCT05415098 -
Study of Safety, Pharmacokinetic and Efficacy of APG-5918 in Advanced Solid Tumors or Lymphomas
|
Phase 1 | |
| Withdrawn |
NCT02547948 -
CD19-targeting CAR T Cells for B Cell Lymphoma
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03258047 -
Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03478514 -
Phase II Palbociclib +Ibrutinib in Mantle Cell Lymphoma
|
Phase 2 | |
| Not yet recruiting |
NCT06058858 -
Incidence and Risks Factors of CMV Reactivation in Patients Receiving of CAR-T Cells for Acute Leukemia and Lymphoma Relapse, a Cohort Study Analysis
|
||
| Recruiting |
NCT06415708 -
Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma
|
Phase 2 | |
| Active, not recruiting |
NCT03307746 -
A Combination of Rituximab and Varlilumab Immunotherapy in Patients With B-cell Lymphoma
|
Phase 1/Phase 2 | |
| Terminated |
NCT03670888 -
A Study to Compare the Bioequivalence and Safety of JHL1101 and Rituximab in CD20 Positive B Cell Lymphoma Patients
|
Phase 1 | |
| Recruiting |
NCT06131801 -
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
|
||
| Recruiting |
NCT06213311 -
A Study of Axicabtagene Ciloleucel and Glofitamab as Second-Line Therapy for Relapsed or Refractory Patients With Large B Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT04008251 -
Humanized CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
|
Phase 1 | |
| Recruiting |
NCT04637763 -
CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)
|
Phase 1 | |
| Recruiting |
NCT04782193 -
a Clinical Research of CD19 and CD22 Targeted Prime CAR-T Cell in Relapsed/Refractory B Cell Lymphoma
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03146533 -
CD19 CART Cells for Patients With Relapse and Refractory CD19+ B-cell Lymphoma.
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05385263 -
Addition of Nivolumab to Anti-CD-19 CAR-T Cells in Patients With Stable/Progressive DLBCL at Lymphodepletion
|
Phase 2 | |
| Recruiting |
NCT03366324 -
Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03929107 -
Interleukin-7 and Chemokine (C-C Motif) Ligand 19-expressing CD19-CAR-T for Refractory/Relapsed B Cell Lymphoma.
|
Phase 2 | |
| Enrolling by invitation |
NCT05332054 -
Long-Term Follow-up Study
|
||
| Recruiting |
NCT04289220 -
Anti-CD19 CAR in PiggyBac Transposon-Engineered T Cells for Relapsed/Refractory B-cell Lymphoma or B-cell Acute Lymphoblastic Leukemia
|
Phase 1 |